GlobalData Report: Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022

Apr 15, 2014
By Applied Clinical Trials Editors

A new report from research and consulting firm GlobalData forecasts the neuropathic pain (NP)—covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia—market value to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a compound annual growth rate of 3.19%.

The report cites the expected launch of seven promising NP treatments before 2022—including Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur—and the expected sales of these pipeline therapies to account for 23.8% of the global NP market.

GlobalData believes that there are opportunities for companies to enter the NP market through the development of novel drugs, provided that their product offerings target some of these unmet needs.

*PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022

Read the full release here.

lorem ipsum